Back to top

AstraZeneca’s VECTRA-01 Trial Targets Next-Generation Gains in Advanced Prostate Cancer

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The Phase III VECTRA-01 study, officially titled “A Phase III, Multi...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN)